Our results were consistent with studies showing SOX2 overexpression in gastric cancer [22], lung squamous cell carcinoma [23], gastrointestinal cancers [12], cervical cancer [24], gliomas [25], and pancreatic carcinoma [3,26]. This evidence concerns the gene SOX2 and central nervous system cancer.